CustoMED
Develops an AI-driven cloud platform that automates the design and 3D printing of patient-specific orthopedic surgical instruments and implants, reducing production time from weeks to minutes.
- CEO / Founder
- Yun Nguyen
- Team Size
- 11-50
- Stage
- Early Stage
- Total Funding
- $6M
- Latest Round
- Seed - $6M - October 2025
- Key Investors
- Longevity Venture Partners; Varana Capital; Flag Capital; Israel Innovation Authority; Avishai Abrahami; Unnamed Orthopedic Implant Company
Technology & Products
Key Products
AI-driven orthopedic platform; Cloud-based surgical planning software; 3D printed patient-specific surgical guides; 3D printed patient-specific implants
Technological Advantage
Proprietary AI algorithms automate the entire design-to-print workflow for orthopedic devices, protected by trade secrets and clinical validation from leading medical institutions.
Differentiation
Value Proposition
Reduces manual design bottlenecks by 90% and operating room time by 30% through automated AI workflows, enabling scalable personalized orthopedics with faster, more precise surgeries.
How They Differentiate
Fully automated AI-driven workflow reduces design time from hours to minutes vs. Materialise's manual-intensive processes; focuses exclusively on orthopedic applications vs. broader medical 3D printing from 3D Systems and Stratasys.
Market & Competition
Target Customers
Orthopedic surgeons, hospitals, surgical centers
Industry Verticals
Medical; Healthcare
Competitors
Materialise; 3D Systems; Stratasys
Growth & Milestones
Growth Metrics
CustoMED has grown to serve over 100 hospitals globally, with reported revenue growth of 200% year-over-year in recent years and expansion into new markets such as Europe and Asia.
Major Milestones
$6M seed funding round completed in October 2025; Platform development from Sheba Medical Center's 3D Printing & Innovation Lab
Notable Customers
Sheba Medical Center (originating hospital), hundreds of successful surgeries performed worldwide